Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis

[21] Haverkamp H(2007)Macrophages and tumor angiogenesis Leukemia 21 2085-2089

[22] Pfistner B(2012)The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages Oncologist 17 871-880

[23] Josting A(2006)Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies Clin Lymphoma Myeloma 7 106-108

[24] Duhmke E(2006)Dual role of macrophages in tumor growth and angiogenesis J Leukoc Biol 80 705-713

[25] Muller-Hermelink K(2010)HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment J Exp Med 207 2439-2453

[26] Diehl V(2010)Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression Cancer Res 70 7465-7475

[27] Levis A(2010)Prognostic significance of absolute lymphocyte count and lymphocyte subsets in lymphomas Prague Med Rep 111 5-11

[28] Anselmo AP(2002)BCL-2 expression in Hodgkin and reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens Blood 100 3935-3941

[29] Ambrosetti A(2007)The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression Am J Clin Pathol 128 958-965

[30] Adamo F(2015)Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era Clin Lymphoma Myeloma Leuk 15 208-213

[21] Haverkamp H(2007)Macrophages and tumor angiogenesis Leukemia 21 2085-2089

[22] Pfistner B(2012)The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages Oncologist 17 871-880

[23] Josting A(2006)Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies Clin Lymphoma Myeloma 7 106-108

[24] Duhmke E(2006)Dual role of macrophages in tumor growth and angiogenesis J Leukoc Biol 80 705-713

[25] Muller-Hermelink K(2010)HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment J Exp Med 207 2439-2453

[26] Diehl V(2010)Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression Cancer Res 70 7465-7475

[27] Levis A(2010)Prognostic significance of absolute lymphocyte count and lymphocyte subsets in lymphomas Prague Med Rep 111 5-11

[28] Anselmo AP(2002)BCL-2 expression in Hodgkin and reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens Blood 100 3935-3941

[29] Ambrosetti A(2007)The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression Am J Clin Pathol 128 958-965

[30] Adamo F(2015)Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era Clin Lymphoma Myeloma Leuk 15 208-213